Published in J Virol on October 24, 2012
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int (2013) 1.11
APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog (2014) 1.07
Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Simian foamy virus infection of rhesus macaques in Bangladesh: relationship of latent proviruses and transcriptionally active viruses. J Virol (2013) 0.90
Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J Virol (2014) 0.89
APOBEC3 Proteins in Viral Immunity. J Immunol (2015) 0.89
Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms. PLoS Pathog (2014) 0.87
AID and APOBECs span the gap between innate and adaptive immunity. Front Microbiol (2014) 0.87
HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J Biol Chem (2013) 0.84
The APOBEC Protein Family: United by Structure, Divergent in Function. Trends Biochem Sci (2016) 0.82
DNA cytosine and methylcytosine deamination by APOBEC3B: enhancing methylcytosine deamination by engineering APOBEC3B. Biochem J (2015) 0.81
Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J Biol Chem (2015) 0.81
Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk. PLoS One (2014) 0.80
Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology (2013) 0.80
APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element. J Mol Biol (2014) 0.80
HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants. J Virol (2014) 0.80
HIV-1 Vpu accessory protein induces caspase-mediated cleavage of IRF3 transcription factor. J Biol Chem (2014) 0.79
Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers. J Virol (2015) 0.79
Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections. J Virol (2014) 0.79
Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage. Antimicrob Agents Chemother (2015) 0.79
APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication. J Virol (2016) 0.78
Host restriction of lentiviruses and viral countermeasures: APOBEC3 and Vif. Viruses (2013) 0.77
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep (2016) 0.77
A Single Nucleotide Polymorphism in Human APOBEC3C Enhances Restriction of Lentiviruses. PLoS Pathog (2016) 0.77
Links between Human LINE-1 Retrotransposons and Hepatitis Virus-Related Hepatocellular Carcinoma. Front Chem (2016) 0.77
Analysis of the N-terminal positively charged residues of the simian immunodeficiency virus Vif reveals a critical amino acid required for the antagonism of rhesus APOBEC3D, G, and H. Virology (2013) 0.76
Mechanism of enhanced HIV restriction by virion coencapsidated cytidine deaminases APOBEC3F and APOBEC3G. J Virol (2016) 0.76
HIV-1 Tropism Determines Different Mutation Profiles in Proviral DNA. PLoS One (2015) 0.76
APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res (2016) 0.76
The virus-induced protein APOBEC3G inhibits anoikis by activation of Akt kinase in pancreatic cancer cells. Sci Rep (2015) 0.76
Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia. PLoS Genet (2016) 0.75
The structural interface between HIV-1 Vif and human APOBEC3H. J Virol (2016) 0.75
Long-term passage of Vif-null HIV-1 in CD4(+) T cells expressing sub-lethal levels of APOBEC proteins fails to develop APOBEC resistance. Virology (2017) 0.75
The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model. Retrovirology (2016) 0.75
An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation. Antiviral Res (2016) 0.75
Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFβ that is critical for Vif function. Retrovirology (2017) 0.75
APOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular Mechanisms. Front Microbiol (2016) 0.75
Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C. J Virol (2016) 0.75
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Macrophages as a source of HIV during opportunistic infections. Science (1997) 3.92
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem (2004) 3.56
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem (2004) 3.01
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res (2010) 2.96
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe (2008) 2.85
Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology (2005) 2.84
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol (2011) 2.50
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol (2006) 2.40
Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology (2006) 1.94
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol (2008) 1.83
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem (2008) 1.68
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res Hum Retroviruses (2005) 1.58
Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr (1994) 1.58
Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol (2008) 1.51
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol (2010) 1.40
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol (2009) 1.38
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol (2010) 1.35
The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol (2010) 1.34
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology (2007) 1.33
Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology (2008) 1.32
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog (2012) 1.29
APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology (2009) 1.27
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
APOBEC3G upregulation by alpha interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. J Gen Virol (2008) 1.23
Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol (2010) 1.22
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog (2007) 1.22
Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol (2010) 1.20
Stably expressed APOBEC3F has negligible antiviral activity. J Virol (2010) 1.15
The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J Virol (2010) 1.05
Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol (2010) 1.04
The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J Virol (2011) 1.04
Calcium phosphate transfection. Curr Protoc Immunol (2001) 0.97
Cell-specific regulation of APOBEC3F by interferons. Acta Biochim Biophys Sin (Shanghai) (2007) 0.92
APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection. Hum Immunol (2010) 0.92
No evidence of an association between the APOBEC3B deletion polymorphism and susceptibility to HIV infection and AIDS in Japanese and Indian populations. J Infect Dis (2010) 0.84
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem (2004) 3.01
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol (2007) 2.95
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol (2007) 2.64
Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding. J Virol (2007) 2.08
High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J Virol (2003) 2.04
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. Proc Natl Acad Sci U S A (2004) 1.91
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc Natl Acad Sci U S A (2006) 1.87
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol (2010) 1.85
Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A (2005) 1.79
High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc Natl Acad Sci U S A (2009) 1.76
Identification of a major restriction in HIV-1 intersubtype recombination. Proc Natl Acad Sci U S A (2005) 1.71
Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology (2006) 1.69
Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. J Virol (2007) 1.60
Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J Virol (2004) 1.59
Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol (2008) 1.59
Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog (2009) 1.53
What does remediation and probation status mean? A survey of emergency medicine residency program directors. Acad Emerg Med (2015) 1.49
Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J Virol (2007) 1.48
Retroviral mutation rates and reverse transcriptase fidelity. Front Biosci (2003) 1.48
Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol (2005) 1.44
APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol (2010) 1.40
P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J Virol (2010) 1.40
Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor. J Virol (2005) 1.36
High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev Technol (2010) 1.33
Probing the HIV-1 genomic RNA trafficking pathway and dimerization by genetic recombination and single virion analyses. PLoS Pathog (2009) 1.30
Sphingolipids function as downstream effectors of a fungal PAQR. Mol Pharmacol (2008) 1.30
HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci U S A (2008) 1.27
APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology (2009) 1.27
Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology (2009) 1.27
Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem (2002) 1.25
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
Real-time PCR analysis of HIV-1 replication post-entry events. Methods Mol Biol (2009) 1.22
Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol (2010) 1.20
Severe restriction of xenotropic murine leukemia virus-related virus replication and spread in cultured human peripheral blood mononuclear cells. J Virol (2011) 1.18
Reporting of complex interventions in clinical trials: development of a taxonomy to classify and describe fall-prevention interventions. Trials (2011) 1.17
Effects of mutations in the human immunodeficiency virus type 1 Gag gene on RNA packaging and recombination. J Virol (2006) 1.17
Validating TrueAllele® DNA mixture interpretation. J Forensic Sci (2011) 1.16
Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS One (2008) 1.14
Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet. J Biol Chem (2008) 1.12
Charged assembly helix motif in murine leukemia virus capsid: an important region for virus assembly and particle size determination. J Virol (2003) 1.11
A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol (2010) 1.08
Dimeric RNA recognition regulates HIV-1 genome packaging. PLoS Pathog (2013) 1.07
Molecular determinants of HIV-1 intersubtype recombination potential. Virology (2007) 1.04
Coassembly and complementation of Gag proteins from HIV-1 and HIV-2, two distinct human pathogens. Mol Cell (2006) 1.04
Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2003) 1.02
Mechanisms and factors that influence high frequency retroviral recombination. Viruses (2011) 1.02
Y586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine-thymine tracts. Proc Natl Acad Sci U S A (2002) 1.01
Zinc finger domain of murine leukemia virus nucleocapsid protein enhances the rate of viral DNA synthesis in vivo. J Virol (2002) 1.01
Genetic recombination between human immunodeficiency virus type 1 (HIV-1) and HIV-2, two distinct human lentiviruses. J Virol (2007) 1.00
High-fidelity medical simulation as an assessment tool for radiology residents' acute contrast reaction management skills. J Am Coll Radiol (2009) 1.00
The "Connection" Between HIV Drug Resistance and RNase H. Viruses (2010) 1.00
Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. J Virol (2011) 0.98
Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation. Virology (2008) 0.98
Comparison of the genetic recombination rates of human immunodeficiency virus type 1 in macrophages and T cells. J Virol (2005) 0.98
Cooperative effect of gag proteins p12 and capsid during early events of murine leukemia virus replication. J Virol (2005) 0.97
Antagonism of human adiponectin receptors and their membrane progesterone receptor paralogs by TNFalpha and a ceramidase inhibitor. Biochemistry (2009) 0.97
Recombinant origin, contamination, and de-discovery of XMRV. Curr Opin Virol (2012) 0.96
The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol (2011) 0.94
Frequent dual initiation in human immunodeficiency virus-based vectors containing two primer-binding sites: a quantitative in vivo assay for function of initiation complexes. J Virol (2004) 0.94
Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J Virol (2006) 0.94
Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes. Proc Natl Acad Sci U S A (2013) 0.94
High frequency of genetic recombination is a common feature of primate lentivirus replication. J Virol (2006) 0.94
Mass spectrometric analysis of the HIV-1 integrase-pyridoxal 5'-phosphate complex reveals a new binding site for a nucleotide inhibitor. J Biol Chem (2004) 0.94
Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques. J Virol (2012) 0.93
Characterization, mapping, and distribution of the two XMRV parental proviruses. J Virol (2011) 0.93
Adiponectin identified as an agonist for PAQR3/RKTG using a yeast-based assay system. J Recept Signal Transduct Res (2009) 0.93
cis-Acting elements important for retroviral RNA packaging specificity. J Virol (2002) 0.92
Determining the frequency and mechanisms of HIV-1 and HIV-2 RNA copackaging by single-virion analysis. J Virol (2011) 0.90
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. J Antimicrob Chemother (2011) 0.90